2-Methyl-3-trifluoromethylaniline, supplied as pharma-grade model 2M3TFMA-PH, is an aromatic amine active pharmaceutical ingredient used in oral tablet, capsule, granule, and sterile injectable manufacturing. The molecular formula is C8H8F3N and the molecular weight is 175.15 g/mol. The free base is hydrophobic and is stored in double low-density polyethylene bags inside an aluminium foil laminate outer bag under nitrogen at 2–8 °C and protected from light. No USP, Ph. Eur., or JP monograph exists for this specific molecule; release criteria are therefore aligned with ICH Q3A, ICH Q3C, ICH Q3D, and Ph. Eur. 2.6.14 for injectable-grade endotoxin control. The pharma-grade designation indicates control of positional isomers, mutagenic impurities, residual solvents, and particle size distribution under a certificate of analysis; technical-grade lots do not provide the same control.

Pharmacopoeial Identity and Release Controls

Because the molecule is used as a free base rather than a preformed salt, the release specification includes assay, related substances, residual solvents, elemental impurities, loss on drying, and water. The specification below is typical for the pharma-grade model; the certificate of analysis reports lot-specific values. Identification is confirmed by infrared absorption spectrophotometry according to Ph. Eur. 2.2.24 and by high-performance liquid chromatography retention time against a reference standard. The trifluoromethyl group at the 3 position is confirmed by 19F nuclear magnetic resonance.

Granulation-grade and micronized grade are both released under the same purity and elemental impurity limits; the particle size attribute is the only physical difference between the two oral grades. The injectable grade adds bacterial endotoxin and particulate matter controls.

Does Particle Size Distribution Shift Content Uniformity During Low-Dose Direct Compression?

Low-dose oral tablet and capsule operations require different particle size ranges than high-dose wet granulation. For direct compression of 1–10 mg strengths, the micronized grade with D90 ≤ 20 µm is specified. This is because large particles of the hydrophobic free base segregate during bin blender discharge and cause blend RSD values above the limit allowed by USP <905>. Content uniformity testing uses USP <905>; a batch is compliant when acceptance value L1 ≤ 15.0. Production-scale evaluation is performed by sampling 10 stratified locations after blending in a 50–100 L bin blender operated at 10–15 rpm for 20–30 min.

Direct compression is performed on a rotary tablet press such as a Korsch XL 400 or equivalent, with 10.0 mm round tooling. The granulation-grade product with D90 150–250 µm is not suitable for direct compression of low-dose strengths because its particle size and density differ from common excipients; the resulting blend has poor flow and content uniformity risk. When wet granulation is selected, the granulation-grade product is pre-blended with microcrystalline cellulose, crospovidone, and lactose monohydrate. Water is sprayed at 5–10 mL/min per kg dry mass in a high-shear mixer with chopper speed 1000–2000 rpm. Wet mass is dried in a fluid-bed dryer at inlet air temperature 50–60 °C until loss on drying is 1.5–2.5% w/w. Dried granules are passed through a 850 µm sieve and collected above 180 µm for compression.

Encapsulation of the granulation-grade product uses an intermittent-motion capsule filler or a dosator-type machine; fill weight control depends on pin compression and powder bed flow. Bulk density and Hausner ratio are measured according to Ph. Eur. 2.9.36. A Hausner ratio above 1.35 indicates cohesive flow and requires the addition of colloidal silicon dioxide at 0.5–1.0% w/w or use of a force-feeder on the encapsulation machine. Size 0 hard gelatin capsules with a fill weight above 300 mg can accept the granulation-grade material; lower fill weights require a lactose monohydrate premix at a ratio of 1:9 API to excipient to maintain homogeneity.

When roller compaction is preferred for moisture-sensitive formulations, the granulation-grade product is compacted at roll force 6–8 kN/cm and milled to granules with D50 100–200 µm. Ribbon density is checked by envelope density or mercury porosimetry, and milled granule flow is measured with a ring shear tester. Roller-compacted granules compressed at 12–18 kN on a rotary press show lower tablet tensile strength than wet-granulated material because of reduced particle plastic deformation; if tablet hardness falls below the acceptance range, microcrystalline cellulose is increased to 30–40% w/w of the formulation.

When Injectable Free Base Handling Requires Pre-Dissolution Acidification and Low Endotoxin Control

The free base is poorly water-soluble at neutral pH; for injectable formulations the API is dissolved in an acidic vehicle such as citrate buffer at pH 3.0–4.0 or 0.9% w/v sodium chloride adjusted to pH 2.5–3.5 with hydrochloric acid. The dissolution temperature is maintained at 20–25 °C because higher temperatures increase oxidative discoloration. The solution is filtered through a 0.22 µm polyvinylidene fluoride membrane under aseptic conditions. Particulate matter is controlled according to USP <788>: not more than 6000 particles per container at ≥10 µm and not more than 600 particles per container at ≥25 µm. Endotoxin release testing uses Ph. Eur. 2.6.14 with a limit of ≤ 0.5 EU/mg for the injectable grade.

If the pH of the bulk solution rises above 5.0, the free base can precipitate, increasing filtration pressure and risking subvisible particulate carryover. Production lines therefore monitor pH in-line before the sterilizing filter. The compound should not be exposed to nitrite-containing excipients or acidic nitrite residues because the aromatic amine can form N-nitroso impurities; a nitrosamine risk assessment under ICH M7 must confirm control below the acceptable intake prior to use in any formulation.

For lyophilized injectable dosage forms, the filtered solution is filled into Type I glass vials and partially stoppered. Freeze-drying uses a shelf temperature ramp from −40 °C to +25 °C over 30–40 h with chamber pressure 50–100 µbar. The cake contains a bulking agent such as mannitol at 2–5% w/v. Residual moisture is controlled by Karl Fischer titration to ≤ 1.0% w/w; primary drying temperature must remain below the collapse temperature of the formulation. A collapsed cake has poor reconstitution and may retain moisture above the limit, causing loss of injectable clarity. Steam sterilization at 121 °C for 15 min is not recommended because the aromatic amine may undergo thermal degradation; aseptic filtration is the preferred sterilization method for this free base.

Compared with technical-grade 2-methyl-3-trifluoromethylaniline, the pharma-grade model 2M3TFMA-PH is controlled for total impurities below 1.0% area, heavy metals below 10 ppm, residual palladium below 10 ppm by ICP-MS where catalytic reduction is used, and bacterial endotoxins for injectable use. The positional isomers 2-methyl-4-trifluoromethylaniline and 2-methyl-5-trifluoromethylaniline are controlled as specified related substances by HPLC on a phenyl-hexyl column with 20 mM phosphate buffer pH 2.5 and acetonitrile gradient. The 3-trifluoromethyl substitution reduces the basicity of the aniline nitrogen relative to non-fluorinated 2-methylaniline; this shift alters salt formation and dissolution in acidic media. The free base is supplied instead of a hydrochloride salt to permit in-situ salt selection during sterile manufacturing and to avoid chloride counterion adjustment in oral formulations. Published data for long-term toxicology of this specific isomer are limited; use as an API therefore assumes that the impurity profile and nitrosamine potential are controlled under an ICH M7 risk assessment before formulation development.